GlaxoSmithKline Stock Analysis

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

USD 41.11  0.25  0.61%

Is it time to welcome GlaxoSmithKline PLC? GlaxoSmithKline PLC Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The modest gains experienced by current holders of GlaxoSmithKline PLC may raise some interest from investors. The stock closed today at a share price of 40.95 on 1,581,905 in trading volume. The company directors and management have been quite successful with maneuvering the stock at opportune times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.57. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. Please check Risk vs Return Analysis.

Search Stock Analysis

The GlaxoSmithKline PLC Stock analysis interface makes it easy to digest most current publicly released information about GlaxoSmithKline PLC as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. GlaxoSmithKline stock analysis module also helps to analyze GlaxoSmithKline PLC price relationship with some important fundamental indicators such as market cap and management efficiency.

GlaxoSmithKline Stock Analysis Notes

The company last dividend was issued on the 14th of May 2020. GlaxoSmithKline PLC had 2:1 split on 12th of November 1991. GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people. To learn more about GLAXOSMITHKLINE P call Emma Walmsley at (44) 20 8047 7807 or check out

GlaxoSmithKline PLC Investment Alerts

GlaxoSmithKline PLC has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9, demonstrating that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has a current ratio of 0.8, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
GLAXOSMITHKLINE P has about 5.12 B in cash with (5.78 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
On 14th of May 2020 GlaxoSmithKline PLC paid $ 0.472 per share dividend to its current shareholders

GlaxoSmithKline PLC Upcoming and Recent Events

Upcoming Quarterly Report22nd of July 2020
Next Earnings Report4th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

GlaxoSmithKline PLC Earnings Estimate

EPSEstimate Date
Quarterly Estimate0.622nd of July 2020
The above chart is showing GlaxoSmithKline PLC normalized analysts earnings estimates for actual as well as future EPS values taken as an average expert opinion over the last few years and projected forward

GlaxoSmithKline PLC SEC Filings

Unclassified Corporate Event
Other Events
Other Events
Other Events. Unclassified Corporate Event
Other Events
Other Events
Other Events
Unclassified Corporate Event

GlaxoSmithKline PLC Thematic Classifications

Institutional Investors

Security TypeSharesValue
Dodge CoxCommon Shares44 M1.7 B
Renaissance Technologies LlcCommon Shares23.1 M874.4 M
Fmr LlcCommon Shares19.5 M737.2 M
Royal Bank Of CanadaCommon Shares17.2 M652.3 M
Price T Rowe Associates IncCommon Shares17.2 M650.4 M
Fisher Asset Management LlcCommon Shares15.5 M588.8 M
Capital International InvestorsCommon Shares14.8 M559.4 M

Market Capitalization

The company currently falls under 'Mega-Cap' category with total capitalization of 117.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The current Return on Investment is estimated to increase to 23.20. The current Return on Average Assets is estimated to increase to 0.07GlaxoSmithKline PLC Return on Average Assets are decreasing as compared to previous years. The last year's value of Return on Average Assets was reported at 0.07. The current Tangible Assets Book Value per Share is estimated to increase to 14.38, while Goodwill and Intangible Assets are estimated to decrease to under 32.9 B. The current Total Liabilities is estimated to decrease to about 57 B. The current Current Liabilities is estimated to decrease to about 22.5 BGlaxoSmithKline PLC management efficiency ratios could be used to measure of how well glaxosmithkline plc is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

Technical Drivers

As of the 2nd of July, GlaxoSmithKline PLC retains the market risk adjusted performance of (0.93), and risk adjusted performance of 0.2348. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for GlaxoSmithKline PLC, which can be compared to its competitors. Please check out GlaxoSmithKline PLC coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if GlaxoSmithKline PLC is priced fairly, providing market reflects its last-minute price of 41.11 per share. Given that GlaxoSmithKline PLC has jensen alpha of 0.2308, we strongly advise you to confirm GlaxoSmithKline PLC's regular market performance to make sure the company can sustain itself at a future point.

GlaxoSmithKline PLC Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of GlaxoSmithKline PLC's momentum and the point in time when GlaxoSmithKline PLC has higher than normal probability directional change. View also all equity analysis or get more info about parabolic sar overlap studies indicator.

GlaxoSmithKline PLC Outstanding Bonds

377372AB3 5.375%04/15/20345.375
377372AD9 5.65%05/15/20185.65
377372AE7 6.375%05/15/20386.375
377372AG2 0.7%03/18/20160.7
377372AH0 2.8%03/18/20232.8
377372AJ6 4.2%03/18/20434.2
377373AB1 0.75%05/08/20150.75
377373AC9 1.5%05/08/20171.5

GlaxoSmithKline PLC Predictive Indicators

GlaxoSmithKline PLC Forecast Models

About GlaxoSmithKline PLC Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how GlaxoSmithKline PLC stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GlaxoSmithKline shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as GlaxoSmithKline PLC. By using and applying GlaxoSmithKline Stock analysis, traders can create a robust methodology for identifying GlaxoSmithKline entry and exit points for their positions.
Last ReportedProjected for 2020
Operating Margin 19.58  22.25 
EBITDA Margin 0.19  0.20 
Gross Margin 0.65  0.63 
Profit Margin 0.14  0.14 
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.

Current GlaxoSmithKline Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GlaxoSmithKline analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GlaxoSmithKline analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
GlaxoSmithKline PLC current and past analyst recommendations published by a number of research institutions as well as average analyst consensus. Most GlaxoSmithKline analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GlaxoSmithKline stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GlaxoSmithKline PLC, talking to its executives and customers, or listening to GlaxoSmithKline conference calls.
GlaxoSmithKline Analyst Advice Details

GlaxoSmithKline Stock Analysis Indicators

Quick Ratio0.54
Fifty Two Week Low31.43
Trailing Annual Dividend Rate1.06
Revenue Growth18.70%
Payout Ratio74.09%
Average Daily Volume Last 10 Day2.54M
Shares Short Prior Month11.2M
Average Daily Volume In Three Month3.6M
Earnings Growth86.80%
Shares Percent Shares Out0.32%
Gross Margins68.18%
Earnings Quarterly Growth88.60%
Forward Price Earnings13.61
Float Shares2.46B
Fifty Two Week High48.25
Fifty Day Average41.43
Two Hundred Day Average42.43
Trailing Annual Dividend Yield2.57%
Please check Risk vs Return Analysis. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page